FDA approves Wellcovorin as first treatment for cerebral folate deficiency

USA—The US Food and Drug Administration (FDA) has approved an expanded use for GSK’s Wellcovorin (leucovorin calcium) tablets, marking a significant breakthrough for patients suffering from cerebral folate deficiency (CFD).

This rare genetic neurological disorder affects brain folate transport in individuals with a confirmed variant in the folate receptor one (FOLR1) gene.

The approval represents the first authorized treatment specifically for cerebral folate deficiency, offering hope to patients who previously had limited therapeutic options.

The decision followed a comprehensive systematic review of published literature, which included case reports containing patient-level data and mechanistic studies that demonstrated the treatment’s potential benefits.

Understanding cerebral folate deficiency

CFD manifests through a range of debilitating symptoms, including seizures, movement disorders, developmental delays, and various neurological complications.

Individuals diagnosed with FOLR1-related cerebral folate transport deficiency (CFD-FOLR1) have faced particularly challenging circumstances due to the absence of approved treatment options until this landmark decision.

The FDA collaborated closely with GSK, the holder of the new drug application (NDA) for Wellcovorin, to update the product labeling.

This collaboration ensured that essential scientific information necessary for the safe and effective use of the drug in both adult and pediatric CFD-FOLR1 patients was properly incorporated.

Regulatory officials highlight patient impact

FDA Commissioner Marty Makary emphasized the importance of this approval for the patient community.

“This approval represents a significant milestone for patients living with cerebral folate transport deficiency due to the FOLR1 variant, a rare genetic condition that has had no FDA-approved treatment options until today,” he stated.

Makary further noted that the action may benefit individuals with FOLR1-related cerebral folate transport deficiency who experience developmental delays with autistic features, potentially addressing multiple aspects of the condition simultaneously.

Demonstrating regulatory efficiency for rare diseases

Tracy Beth Hoeg, acting director of the FDA Center for Drug Evaluation and Research, highlighted the broader implications of this approval.

 She explained that the authorization of leucovorin for CFD-FOLR1 demonstrates the agency’s commitment to rapidly identifying effective treatments for ultra-rare diseases while maintaining rigorous evidentiary standards.

Hoeg also pointed to the approval as an important example of how observational or “real world” evidence can support FDA approvals when a product demonstrates clear clinical benefits compared with the natural progression of a disease.

Broader biosimilar regulatory updates

Prior to this approval, the FDA had updated its regulatory framework for biosimilar medicines to facilitate reductions in domestic drug prices.

The regulator introduced new draft guidance that relaxed certain regulations surrounding biosimilar development, with the goal of streamlining and simplifying the approval process for these alternative treatment options.